---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-004199"
form_type: "8-K"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:26:11.198722+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OSR Holdings subsidiary Vaximm gets binding term sheet for VXM01 license: $30M upfront, $815M milestones

## Summary
- Vaximm, OSR Holdings' subsidiary, enters binding term sheet with BCM Europe for global exclusive license of VXM01.
- Upfront payment of $30M (50% cash, 50% digital assets) and up to $815M in clinical, regulatory, and commercial milestones.
- Definitive agreement targeted by end of May 2026, subject to fairness opinion, board review, and final documentation.
- BCM Europe, the largest OSRH shareholder, will establish a fund (BCM Decentralized Science Investors I) as licensee.
- VXM01 is an oral T-cell vaccination platform targeting VEGFR-2; has shown clinical activity and safety in multiple cancers.

## SEC filing metadata
- accession: 0001213900-26-004199
- form_type: 8-K
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000121390026004199/0001213900-26-004199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000121390026004199/ea0272738-8k_osrhold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-004199
- JSON: https://secwatch.observer/filing/0001213900-26-004199.json
- Plain text: https://secwatch.observer/filing/0001213900-26-004199.txt

## Key facts
- Material Agreements
  OSR Holdings, Inc. entered into Binding Term Sheet with BCM Europe AG valued at $30.0 million (comprised of $15.0 million in cash and $15.0 million in digital assets) and up to $81 (effective 2025-01-13).
  - Action: entry
  - Agreement: license
  - Counterparty: BCM Europe AG
  - Value: $30.0 million (comprised of $15.0 million in cash and $15.0 million in digital assets) and up to $81
  - Effective: 2025-01-13
  source text: On January 13, 2025, Vaximm AG, a wholly-owned subsidiary of OSR Holdings, Inc. (the “Company”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”), the largest shareholder of the Company, relating to a proposed global exclusive license of Vaximm’s VXM01 oral cancer immunotherapy platform.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000121390026004199/0001213900-26-004199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.